Ann Rheum Dis. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

[tetano]

Ann Rheum Dis. 2020 Apr 29. pii: annrheumdis-2020-217407. doi: 10.1136/annrheumdis-2020-217407. [Epub ahead of print]
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.


Matucci-Cerinic M^#1, Bruni C^#2, Allanore Y³, Clementi M^4,5, Dagna L^6,7, Damjanov NS⁸, de Paulis A⁹, Denton CP¹⁰, Distler O¹¹, Fox D¹², Furst DE^2,13, Khanna D¹⁴, Krieg T¹⁵, Kuwana M¹⁶, Lee EB¹⁷, Li M¹⁸, Pillai S¹⁹, Wang Y²⁰, Zeng X²¹, Taliani G²².

Author information




Abstract

Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
? Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



KEYWORDS:

autoimmune diseases; hydroxychloroquine; scleroderma; systemic


PMID:32349982DOI:10.1136/annrheumdis-2020-217407